The US Food and Drug Administration has awarded Priority Review status to a supplemental Biologics License Application for Tecentriq (atezolizumab) in non-small cell lung cancer (NSCLC).
Swiss firm Roche (ROG: SIX) is bidding to broaden the label for the checkpoint inhibitor, to include first-line monotherapy for people with advanced non-squamous and squamous forms of NSCLC.
While Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) remains dominant in the field of checkpoint inhibition, Tecentriq represents an increasingly important option for many people with cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze